首页 › 多发性骨髓瘤 › 犹他州 › Salt Lake City
Salt Lake City UT 多发性骨髓瘤临床试验
21项针对 多发性骨髓瘤的研究正在 Salt Lake City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
招募中3 期
- Research Site, Salt Lake City
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Utah Cancer Specialists, Salt Lake City
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
招募中3 期
- LDS Hospital, Salt Lake City
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Intermountain Healthcare, Salt Lake City
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
招募中3 期
- Huntsman Cancer Institute, Salt Lake City
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- LDS Hospital, Salt Lake City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
招募中1/2 期
- Huntsman Cancer Institute /ID# 271618, Salt Lake City
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
招募中2 期
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
招募中2 期
- Huntsman Cancer Institute, Salt Lake City
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Salt Lake City
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
招募中1/2 期
- Huntsman Cancer Institute /ID# 272575, Salt Lake City
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
招募中2 期
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- Huntsman Cancer Center Institute University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- University of Utah, Salt Lake City
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
招募中观察性研究
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
招募中1 期
- Huntsman Cancer Institute, University of Utah, Salt Lake City
其他城市的 多发性骨髓瘤试验
- New York City, NY60 项研究
- Atlanta, GA42 项研究
- Boston, MA42 项研究
- Houston, TX38 项研究
- Durham, NC37 项研究
- Nashville, TN32 项研究
- Denver, CO27 项研究
- Rochester, MN24 项研究
- St. Louis, MO24 项研究
- Columbus, OH24 项研究
- Baldwin Park, CA23 项研究
- Edison, NJ22 项研究
Salt Lake City的其他研究
- 非小细胞肺癌31 项研究
- 癌症（所有类型）27 项研究
- 乳腺癌27 项研究
- 结直肠癌22 项研究
- 肺癌21 项研究
- 黑色素瘤21 项研究
- 转移性癌症20 项研究
- 卵巢癌19 项研究
- 肥胖症18 项研究
- 急性髓系白血病17 项研究
- 心力衰竭17 项研究
- 前列腺癌15 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。